McKesson, Walmart to pool buying power for generic meds

Wal-Mart Pharmacy
Wal-Mart Pharmacy

Retailing giant Walmart and global drug wholesaler McKesson ($MCK) would both like to improve their bottom lines and think that pooling their purchasing power for generic meds can help them do that.

The two, which have worked together for years, Monday announced their plan to buy generic drugs jointly and the continuation of a long-term distribution agreement but provided no details about what that might mean in terms of dollars invested or savings that might be expected.

“Expanding our relationship to include a sourcing partnership for generics makes economic and strategic sense for both of us,” Mark Walchirk, president of McKesson U.S. Pharmaceutical, said in a statement. “By bringing together our respective scale and sourcing expertise, we will make our businesses stronger and create more value for our customers and patients.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

While Bentonville, AR-based Walmart does not break out its pharmacy business separately, CNBC says that the Wal-Mart stores are estimated to do about $19 billion a year in pharmacy sales. The network says that in August Walmart reported the margins on drug sales had been shaved by lower reimbursement rates from drug plan administers and by fewer customers paying cash for their meds.

The deal comes at a key time for McKesson, which is whacking jobs to cut costs. In March, San Francisco-based McKesson confirmed it had already eliminated 1,600 jobs, about 4% of its workforce. The company said after a review in January "the company determined that reductions to our workforce would be necessary to align our cost structure with our business needs."

That comes after a couple of years of expanding. In March, the wholesaler announced it would spend $2.23 billion (CA$3 billion) to buy Rexall Health from Katz Group, picking up 470 retail pharmacies in Canada and about 8,600 employees.

- here’s the release

Related Articles: 
Drug distributor McKesson laying off 1,600
McKesson nails down another international supply chain deal

Read more on

Suggested Articles

Having only just completed an expansion in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K.

The FDA has come down on a small U.S. drugmaker for taking a skin medication to market even though there were out-of-spec test results at release.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.